Our Insights
Hazelbrook shares its deep expertise and professional knowledge to bring you news, legal insights and media updates.
MAC to the Future: What Mayne Pharma Means for Deal Drafting
The Supreme Court of New South Wales has delivered a significant ruling in Re Mayne Pharma Group Limited [2025] NSWSC 1204, marking one of the most detailed examinations of material adverse change (MAC) clauses in Australian M&A history. It is a decisive moment for deal makers and legal practitioners, confirming that MAC provisions are not exit ramps for buyer’s remorse.
APRA’s 2025–26 Corporate Plan: Getting the Balance Right Between Resilience and Efficiency
APRA’s 2025-26 Corporate Plan sets out the regulator’s strategic objectives for the next four years and supervisory priorities for the next 12 to 18 months.
MAC ATTACK: The Power and Pitfalls of Material Adverse Change Clauses in M&A Deals
The high-stakes legal standoff between Cosette Pharmaceuticals and Mayne Pharma offers a timely reminder of a critical issue for both buyers and sellers in mergers and acquisitions: how material adverse change (MAC) clauses are drafted, negotiated, and ultimately enforced.
Crypto-Linked Products and AFSL Requirements: Key Takeaways from the Recent Court Decision
The Full Federal Court has overturned a previous decision that found Block Earner’s fixed-yield “Earner” product to be a financial product requiring an Australian financial services licence (AFSL).
ASIC's Regulatory Focus for 2025: Enforcement Actions and Priorities
Staying true to its enforcement priorities for 2025, the Australian Securities and Investments Commission (ASIC) has launched several enforcement actions against businesses in breach of various regulations and misconduct. This article compiles some notable enforcement actions by ASIC in the first quarter of 2025, linking those enforcement actions to its respective priorities.
Load Next 5
↓